Enabling Proregenerative Medical Devices via Citrate‐Based Biomaterials: Transitioning from Inert to Regenerative Biomaterials

Regenerative medicine aims to restore tissue and organ function without the use of prosthetics and permanent implants. However, achieving this goal has been elusive, and the field remains mostly an academic discipline with few products widely used in clinical practice. From a materials science perspective, barriers include the lack of proregenerative biomaterials, a complex regulatory process to demonstrate safety and efficacy, and user adoption challenges. Although biomaterials, particularly biodegradable polymers, can play a major role in regenerative medicine, their suboptimal mechanical and degradation properties often limit their use, and they do not support inherent biological processes that facilitate tissue regeneration. As of 2020, nine synthetic biodegradable polymers used in medical devices are cleared or approved for use in the United States of America. Despite the limitations in the design, production, and marketing of these devices, this small number of biodegradable polymers has dominated the resorbable medical device market for the past 50 years. This perspective will review the history and applications of biodegradable polymers used in medical devices, highlight the need and requirements for regenerative biomaterials, and discuss the path behind the recent successful introduction of citrate‐based biomaterials for manufacturing innovative medical products aimed at improving the outcome of musculoskeletal surgeries. This perspective reviews the history and applications of biodegradable polymers used in medical devices marketed in the United States of America, highlights the need and requirements for regenerative biomaterials, and discusses the path behind the recent successful introduction of citrate‐based biomaterials for the manufacture of innovative medical products aimed at improving the outcome of musculoskeletal surgeries.